Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 16/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | IGF1R | P08069 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12975568 | 1.00 | PIK3CG (0.56) | PIK3CGKMT2AUSP2HTTIGF1R | |
| SCHEMBL5334781 | 0.91 | PIK3CG (0.68) | PIK3CG | |
| SCHEMBL5334776 | 0.91 | PIK3CG (0.68) | PIK3CG | |
| SCHEMBL2877631 | 0.88 | PIK3CG (0.60) | PIK3CGHTT | |
| SCHEMBL2882245 | 0.82 | KMT2A (0.62) | KMT2AUSP2HTT | |
| SCHEMBL5379124 | 0.81 | PIK3CG (0.66) | PIK3CG | |
| SCHEMBL12975575 | 0.81 | PIK3CG (0.61) | PIK3CGKMT2A | |
| SCHEMBL2883082 | 0.81 | PIK3CG (0.61) | PIK3CGKMT2A | |
| SCHEMBL2880401 | 0.81 | PIK3CG (0.60) | PIK3CG | |
| SCHEMBL12975577 | 0.81 | PIK3CG (0.60) | PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846925-B2 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2010-12-07 | — | — | US | claimed |
| US-20090042773-A1 | P13 kinase gamma inhibitors for the treatment of anaemia | MERCK SERONO SA (CH) | 2009-02-12 | — | — | US | claimed |
| US-20060122176-A1 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2006-06-08 | — | — | US | claimed |
| US-7846925-B2 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2010-12-07 | — | — | US | disclosed |
| US-20090306069-A1 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES | LABORATOIRES SERONO S.A. (CH) | 2009-12-10 | — | — | US | disclosed |
| US-20060122176-A1 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2006-06-08 | — | — | US | disclosed |
| US-20050222225-A1 | Use of compounds for increasing spermatozoa motility | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (NL) | 2005-10-06 | — | — | US | disclosed |
| EP-1531813-A1 | USE OF COMPOUNDS FOR INCREASING SPERMATOZOA MOTILITY | Applied Research Systems ARS Holding N.V. (AN) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004006916-A1 | USE OF COMPOUNDS FOR INCREASING SPERMATOZOA MOTILITY | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (AN) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306069-A1 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES | ZAP70, BRCA1, ZYX | PIK3CG 1265/4885KMT2A 3006/4885USP2 4104/4885 |
| US-20090042773-A1 | P13 kinase gamma inhibitors for the treatment of anaemia | PDPK1, PRKD3, PRKD1 | PIK3CG 52/4885KMT2A 1230/4885USP2 2689/4885 |
| US-20050222225-A1 | Use of compounds for increasing spermatozoa motility | CATSPER1, PI4KB, MAN2B2 | PIK3CG 110/4885KMT2A 2969/4885USP2 3685/4885 |
| US-20060122176-A1 | Azolidinone-vinyl fused-benzene derivatives | BRCA1, ZAP70, F13B | PIK3CG 1318/4885KMT2A 3104/4885USP2 3943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.